image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 230.5
-3.71 %
$ 166 B
Market Cap
43.57
P/E
1. INTRINSIC VALUE

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products.[ Read More ]

The intrinsic value of one DHR stock under the base case scenario is HIDDEN Compared to the current market price of 230 USD, Danaher Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DHR

image
FINANCIALS
23.9 B REVENUE
-24.09%
5.2 B OPERATING INCOME
-40.12%
4.22 B NET INCOME
-41.45%
7.16 B OPERATING CASH FLOW
-15.91%
-7.08 B INVESTING CASH FLOW
-216.97%
-273 M FINANCING CASH FLOW
89.38%
5.8 B REVENUE
0.96%
958 M OPERATING INCOME
-17.98%
818 M NET INCOME
-9.81%
1.51 B OPERATING CASH FLOW
6.77%
-606 M INVESTING CASH FLOW
-68.33%
-845 M FINANCING CASH FLOW
85.21%
Balance Sheet Decomposition Danaher Corporation
image
Current Assets 13.9 B
Cash & Short-Term Investments 5.86 B
Receivables 3.92 B
Other Current Assets 4.15 B
Non-Current Assets 70.6 B
Long-Term Investments 5 M
PP&E 4.55 B
Other Non-Current Assets 66 B
Current Liabilities 8.27 B
Accounts Payable 1.77 B
Short-Term Debt 1.88 B
Other Current Liabilities 4.63 B
Non-Current Liabilities 22.7 B
Long-Term Debt 17.7 B
Other Non-Current Liabilities 5.06 B
EFFICIENCY
Earnings Waterfall Danaher Corporation
image
Revenue 23.9 B
Cost Of Revenue 9.86 B
Gross Profit 14 B
Operating Expenses 8.83 B
Operating Income 5.2 B
Other Expenses 981 M
Net Income 4.22 B
RATIOS
58.74% GROSS MARGIN
58.74%
21.77% OPERATING MARGIN
21.77%
19.94% NET MARGIN
19.94%
8.91% ROE
8.91%
5.64% ROA
5.64%
6.06% ROIC
6.06%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Danaher Corporation
image
Net Income 4.22 B
Depreciation & Amortization 2.17 B
Capital Expenditures -1.38 B
Stock-Based Compensation 306 M
Change in Working Capital -393 M
Others 1.32 B
Free Cash Flow 5.78 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Danaher Corporation
image
Wall Street analysts predict an average 1-year price target for DHR of $287 , with forecasts ranging from a low of $270 to a high of $315 .
DHR Lowest Price Target Wall Street Target
270 USD 17.14%
DHR Average Price Target Wall Street Target
287 USD 24.70%
DHR Highest Price Target Wall Street Target
315 USD 36.66%
4. DIVIDEND ANALYSIS
0.10% DIVIDEND YIELD
0.27 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Danaher Corporation
image
Sold
0-3 MONTHS
255 K USD 1
3-6 MONTHS
17.1 M USD 5
6-9 MONTHS
42.6 M USD 8
9-12 MONTHS
817 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 26, 2024
Sell 255 K USD
Couchara Georgeann
SVP, Human Resources
- 952
268.365 USD
3 months ago
Jul 31, 2024
Sell 2.52 M USD
Blair Rainer
President & CEO
- 9007
280 USD
3 months ago
Aug 01, 2024
Sell 1.1 M USD
FILLER LINDA
Director
- 3928
279.5 USD
3 months ago
Aug 01, 2024
Sell 4.53 M USD
McGrew Matthew
EVP & Chief Financial Officer
- 16172
279.8389 USD
3 months ago
Jul 25, 2024
Sell 2.64 M USD
Ellis Brian W
Senior Vice President - GC
- 9600
275.16 USD
3 months ago
Jul 25, 2024
Sell 3.92 M USD
Raskas Daniel
SVP - Corporate Development
- 14507
270.5144 USD
6 months ago
May 16, 2024
Sell 2.39 M USD
Blair Rainer
President & CEO
- 9005
265 USD
6 months ago
May 14, 2024
Sell 4.87 M USD
Blair Rainer
President & CEO
- 19085
255 USD
6 months ago
May 10, 2024
Sell 5.37 M USD
McGrew Matthew
EVP & Chief Financial Officer
- 21203
253.0752 USD
6 months ago
May 10, 2024
Sell 4.03 M USD
McGrew Matthew
EVP & Chief Financial Officer
- 15931
252.945 USD
6 months ago
May 10, 2024
Sell 2.34 M USD
McGrew Matthew
EVP & Chief Financial Officer
- 9243
253.1901 USD
6 months ago
May 02, 2024
Sell 172 K USD
SPOON ALAN G
Director
- 708
243.58 USD
6 months ago
Apr 25, 2024
Sell 5.62 M USD
Weidemanis Joakim
Executive Vice President
- 22433
250.46 USD
6 months ago
Apr 24, 2024
Sell 1 M USD
Ellis Brian W
Senior Vice President - GC
- 4000
250.01 USD
6 months ago
Apr 24, 2024
Sell 9.51 M USD
Blair Rainer
President & CEO
- 38170
249.03 USD
6 months ago
Apr 24, 2024
Sell 2.25 M USD
Blair Rainer
President & CEO
- 9005
250 USD
8 months ago
Feb 26, 2024
Sell 5.99 M USD
Raskas Daniel
SVP - Corporate Development
- 23757
252 USD
9 months ago
Feb 15, 2024
Sell 826 K USD
LOHR WALTER G
Director
- 3289
251.15 USD
9 months ago
Feb 13, 2024
Sell 205 K USD
Couchara Georgeann
SVP, Human Resources
- 844
242.66 USD
9 months ago
Feb 13, 2024
Sell 431 K USD
Couchara Georgeann
SVP, Human Resources
- 1778
242.68 USD
9 months ago
Feb 06, 2024
Sell 817 K USD
List Teri
Director
- 3289
248.32 USD
1 year ago
Aug 21, 2023
Sell 148 K USD
Gutierrez-Ramos Jose-Carlos
SVP, Chief Science Officer
- 590
250.54 USD
1 year ago
Jul 28, 2023
Sell 2.92 M USD
Raskas Daniel
SVP - Corporate Development
- 11213
260.6485 USD
1 year ago
Jul 28, 2023
Sell 1.89 M USD
FILLER LINDA
Director
- 7268
260.2501 USD
1 year ago
Jul 28, 2023
Sell 760 K USD
FILLER LINDA
Director
- 2922
260.2603 USD
1 year ago
Jul 26, 2023
Sell 5.91 M USD
Weidemanis Joakim
Executive Vice President
- 22439
263.4178 USD
1 year ago
Jul 26, 2023
Sell 919 K USD
List Teri
Director
- 3490
263.3 USD
1 year ago
May 31, 2023
Sell 4.54 M USD
Raskas Daniel
SVP - Corporate Development
- 19847
228.5 USD
1 year ago
May 05, 2023
Sell 841 K USD
LOHR WALTER G
Director
- 3490
240.884 USD
1 year ago
May 04, 2023
Sell 2.44 M USD
Weidemanis Joakim
Executive Vice President
- 9934
245.27 USD
1 year ago
May 04, 2023
Sell 170 K USD
Couchara Georgeann
SVP, Human Resources
- 695
245.27 USD
1 year ago
May 01, 2023
Sell 121 K USD
Gutierrez-Ramos Jose-Carlos
SVP, Chief Science Officer
- 500
242.1928 USD
1 year ago
Jan 25, 2023
Sell 589 K USD
Stevens Raymond C
Director
- 2230
264.235 USD
2 years ago
Feb 25, 2022
Sell 1.05 M USD
Honeycutt Jennifer
Executive Vice President
- 3777
278.6355 USD
1 year ago
Nov 28, 2022
Sell 1.76 M USD
Weidemanis Joakim
Executive Vice President
- 6608
266.44 USD
1 year ago
Nov 28, 2022
Sell 774 K USD
Weidemanis Joakim
Executive Vice President
- 2900
266.98 USD
2 years ago
Nov 15, 2022
Sell 457 K USD
Couchara Georgeann
SVP, Human Resources
- 1684
271.613 USD
2 years ago
Nov 15, 2022
Sell 54.3 K USD
Couchara Georgeann
SVP, Human Resources
- 200
271.615 USD
2 years ago
Nov 11, 2022
Sell 3.08 M USD
McGrew Matthew
EVP & Chief Financial Officer
- 11213
274.963 USD
2 years ago
Nov 10, 2022
Sell 2.18 M USD
Honeycutt Jennifer
Executive Vice President
- 8211
265 USD
2 years ago
Oct 25, 2022
Sell 126 K USD
SPOON ALAN G
Director
- 500
252.93 USD
2 years ago
Aug 15, 2022
Sell 7.5 M USD
Blair Rainer
President & CEO
- 25000
300 USD
2 years ago
Jul 25, 2022
Sell 1.32 M USD
Weidemanis Joakim
Executive Vice President
- 4899
270.215 USD
2 years ago
Jul 22, 2022
Sell 1.07 M USD
LOHR WALTER G
director:
- 3906
273.84 USD
2 years ago
May 16, 2022
Bought 24.8 K USD
RALES MITCHELL P
Chairman of Exec. Committee
+ 100
247.89 USD
2 years ago
Apr 25, 2022
Sell 1.66 M USD
Weidemanis Joakim
Executive Vice President
- 6500
255.735 USD
2 years ago
Feb 02, 2022
Sell 1.58 M USD
Ellis Brian W
Senior Vice President - GC
- 5365
293.9884 USD
2 years ago
Jan 31, 2022
Sell 5.85 M USD
Weidemanis Joakim
Executive Vice President
- 20508
285.2425 USD
7. News
Revving Up: 2 Underperforming Dividend Giants Ready To Outshine Two high-quality dividend stocks are finally positioned for a strong rebound. After a period of underperformance, their growth potential is back in focus. These companies have adapted well to recent challenges, enhancing their strategies to boost shareholder returns. Their fundamentals are solid and undervalued. With robust dividends and renewed growth trajectories, both stocks stand ready to outperform. Ideal picks for investors seeking stability and upside potential. seekingalpha.com - 2 days ago
Danaher (DHR) Reliance on International Sales: What Investors Need to Know Examine Danaher's (DHR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock. zacks.com - 2 weeks ago
Want to Grow a Passive Income Snowball? Buy These 7 Elite Dividend Growth Stocks. These seven companies are transforming steady profits into rising passive income streams for investors. fool.com - 3 weeks ago
Understanding Danaher's Cautiousness Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article. seekingalpha.com - 3 weeks ago
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating On Tuesday, Danaher Corp DHR reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. benzinga.com - 3 weeks ago
Danaher Q3 Earnings Surpass Estimates, Diagnostics Sales Up Y/Y DHR's third-quarter earnings and sales surpass estimates, benefiting from the solid performance of its Life Sciences and Diagnostics segments. zacks.com - 3 weeks ago
Stock Markets Taper on High Valuations, Upcoming Election In two weeks we potentially could see a number of prominent news items which could change the trajectory of stock market enthusiasm. zacks.com - 3 weeks ago
Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript Danaher Corporation (NYSE:DHR ) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Tycho Peterson - Jefferies Michael Ryskin - Bank of America Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Scott Davis - Melius Research Puneet Souda - Leerink Partners Dan Leonard - UBS Jack Meehan - Nephron Research Operator My name is Ashley and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Third Quarter 2024 Earnings Results Conference Call. seekingalpha.com - 3 weeks ago
Danaher (DHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 3 weeks ago
Danaher (DHR) Tops Q3 Earnings and Revenue Estimates Danaher (DHR) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $2.02 per share a year ago. zacks.com - 3 weeks ago
Danaher beats quarterly profit estimates on strong demand for bioprocessing unit Danaher on Tuesday beat Wall Street estimates for third-quarter profit on strong demand for its diagnostics and bioprocessing businesses, alongside growth in its molecular testing unit. reuters.com - 3 weeks ago
Danaher Reports Third Quarter 2024 Results WASHINGTON , Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024.  All results in this release reflect only continuing operations unless otherwise noted. prnewswire.com - 3 weeks ago
8. Profile Summary

Danaher Corporation DHR

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 166 B
Dividend Yield 0.10%
Description Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Contact 2200 Pennsylvania Avenue, NW, Washington, DC, 20037-1701 https://www.danaher.com
IPO Date Dec. 29, 1978
Employees 61000
Officers Ms. Georgeann F. Couchara Senior Vice President of Human Resources Mr. William H. King IV Senior Vice President of Strategic Development Mr. Daniel A. Raskas J.D. Senior Vice President of Corporate Development Mr. Steven M. Rales Co-Founder & Chairman Mr. Matthew R. McGrew Chief Financial Officer & Executive Vice President Mr. John Bedford Vice President of Investor Relations Mr. Rainer M. Blair President, Chief Executive Officer & Director Mr. Mitchell P. Rales Co-Founder & Director Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Senior Vice President & Chief Science Officer Mr. Christopher M. Bouda Vice President & Chief Accounting Officer